Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Join us for February's Bio-Expo Live, a three-day virtual event designed to empower biopharma professionals with the chance to conveniently explore the newest equipment and offerings in Upstream Bioprocessing, Downstream Bioprocessing and Bioprocess Quality, Data, and Analytical Solutions.
Join MasterControl for an expert panel on the future of cell and gene therapy (CGT) manufacturing. Learn how leading organizations are tackling regulatory complexity, cGMP execution, and digital transformation as CGT scales to commercialization. Gain practical strategies to embed quality at the source, harmonize global compliance, and leverage digital tools to build resilient, future-ready CGT operations. Click here to learn more.
By Geethashri Ananda, Ph.D., University of Pittsburgh Cell and gene therapy (CGT) has evolved from a purely experimental field into one rapidly advancing toward large-scale manufacturing and commercialization, with dozens of products already receiving regulatory approval. This transition introduces a new set of challenges that extend beyond the digitalization of manufacturing, analytical, and quality management systems.
By Geethashri Ananda, Ph.D., University of Pittsburgh Cell and gene therapy (CGT) has evolved from a purely experimental field into one rapidly advancing toward large-scale manufacturing and commercialization, with dozens of products already receiving regulatory approval. This transition introduces a new set of challenges that extend beyond the digitalization of manufacturing, analytical, and quality management systems.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
